Long-Term Treatment with Ruxolitinib for Patients With Myelofibrosis: 5-Year Update From the Randomized, Double-Blind, Placebo-Controlled, Phase 3 COMFORT-I Trial

The final COMFORT-I results continue to support ruxolitinib as an effective treatment for patients with intermediate-2/high-risk myelofibrosis.

 J Hematol Oncol

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.